725 poster Assessment of quality of life of nasopharyngeal carcinoma patients with EORTC QLQ c30 and H&N 30: Turkish Oncology Group, Head and Neck Working Party Study

Purpose To assess the added prognostic value for overall survival (OS) of baseline health-related quality of life (HRQOL) and of early changes in HRQOL among patients with localized head and neck cancer (HNC) treated with radiation therapy. Patients and Methods All 540 patients with HNC who participated in a randomized trial completed two HRQOL instruments before radiation therapy: the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and the Head and Neck Radiotherapy Questionnaire. Six months after the end of radiation therapy, 497 trial participants again completed the two HRQOL instruments. During the follow-up, 179 deaths were observed. Multivariate Cox proportional hazards models were used to test whether HRQOL variables, baseline and change, provided additional prognostic value beyond recognized prognostic factors. Results The baseline EORTC QLQ-C30 physical functioning (PF) score was an independent predictor of OS. The hazard ratio (HR) associated with a 10-point increment in baseline PF was 0.87 (95% CI, 0.81 to 0.94). In multivariate models, the change in HRQOL was significantly associated with OS for most HRQOL dimensions. Among these, PF change was the strongest predictor. The magnitude of the association between PF change and survival decreased over time. At 1 year, the HR associated with a positive PF change of 10 points was 0.75 (95% CI, 0.68 to 0.83). After PF is taken into account, no other HRQOL variable was associated with survival. Conclusion Our findings indicate that both baseline PF and PF change provide added prognostic value for OS beyond established predictors in patients with HNC. Assessing HRQOL could help better predict survival of cancer patients.

Download Full-text

Prospective, Longitudinal Quality-of-Life Study of Patients With Head and Neck Cancer: A Feasibility Study Including the EORTC QLQ-C30

Otolaryngology ◽

10.1016/s0194-5998(97)70246-8 ◽

1997 ◽

Vol 116 (6) ◽

pp. 666-673 ◽

Cited By ~ 76

Author(s):

Eva Hammerlid ◽

Kristin Bjordal ◽

Marianne Ahlner-ELMQVIST ◽

Magnus Jannert ◽

Stein Kaasa ◽

...

Keyword(s):

Quality Of Life ◽

Head And Neck Cancer ◽

Psychological Distress ◽

Pilot Study ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Eortc Qlq C30 ◽

Eortc Qlq

Despite modern advances in the treatment of head and neck cancer, the survival rate fails to improve. Considering the different treatment modalities involved, quality of life has been thought of as an additional end point criterion for use in clinical trials. A Nordic protocol to measure the quality of life of head and neck cancer patients before, during, and after treatment was established. Before the study, a pilot study was done with this protocol. The main purpose of this pilot study was to find out whether this cancer population would answer quality-pf-life questionnaires repeatedly (six times) over a 1-year period and whether the chosen questionnaires—a core questionnaire (European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30)), a tumor-specific questionnaire, and a psychological distress measure (Hospital Anxiety and Depression scale (HAD))—were sensitive for changes to functions and symptoms during the study year. The results presented in this article all refer to the pilot study. Forty-eight consecutive patients agreed to participate in the study. The most common tumor locations were the oral cavity (17) and the larynx (12). Almost all patients received combined treatment: 45 of 48 radiation therapy, 18 of 48 chemotherapy, and 17 of 48 surgery. After the primary treatment, 40 patients had complete tumor remission. Four of the 48 patients did not answer any questionnaires and were therefore excluded from the study. Of the remaining 44 patients, 3 died during the study year, and another 6 withdrew for various reasons. Thirty-five (85%) of the 41 patients alive at the 1-year follow-up answered all six questionnaires and thus completed the study. Mailed questionnaires were used throughout the study. All questionnaires were well accepted and found to be sensitive to changes during the study year. The greatest variability was found for symptoms and functions related specifically to head and neck cancer. The symptoms were swallowing difficulties, hoarse voice, sore mouth, dry mouth, and problems with taste. They all showed the same pattern, with an increase of symptoms during and just after finishing the treatment. The HAD scale revealed a high level of psychological distress, with 21% probable cases of psychiatric morbidity at diagnosis. In conclusion, it was shown that the study design and questionnaires were feasible for the forthcoming prospective quality-of-life assessment of Swedish and Norwegian head and neck cancer patients.

Download Full-text

PCN378 - MINIMALLY IMPORTANT DIFFERENCES FOR INTERPRETING EORTC QLQ-C30 SCORES IN MELANOMA, BREAST CANCER AND HEAD AND NECK CANCER PATIENTS ON BEHALF OF THE EORTC BREAST, HEAD AND NECK, MELANOMA AND QUALITY OF LIFE GROUPS

Value in Health ◽

10.1016/j.jval.2018.09.460 ◽

2018 ◽

Vol 21 ◽

pp. S78

Author(s):

Z.J. Musoro ◽

C. Coens ◽

F. Fiteni ◽

K. Pogoda ◽

F. Cardoso ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Head And Neck Cancer ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Eortc Qlq C30 ◽

Eortc Qlq ◽

Head And Neck Melanoma

Download Full-text

Assessment of Quality of Life in Recurrent and Metastatic Head and Neck Cancer after Oral Metronomic Chemotherapy: A Prospective Interventional Study

JOURNAL FOR CLINICAL AND DIAGNOSTIC RESEARCH ◽

10.7860/jcdr/2021/48916.15089 ◽

2021 ◽

Author(s):

Vipul Nautiyal ◽

Viney Kumar ◽

Anshika Arora ◽

Meenu Gupta ◽

Shivani Mehra ◽

...

Keyword(s):

Quality Of Life ◽

Head And Neck ◽

Symptom Score ◽

Eastern Cooperative Oncology Group ◽

Metronomic Chemotherapy ◽

P Value ◽

Life Questionnaire ◽

Eortc Qlq C30 ◽

Eortc Qlq

Introduction: Most of the Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinomas (HNSCC) patients are treated only by palliative treatment. Metronomic Chemotherapy (MC) low doses is an emerging therapeutic option in these patients. It exerts tumour angiogenesis, stimulate anticancer immune response, induces tumour dormancy and offers a significant improvement in Quality of Life (QoL) with minimal toxicity. Aim: To assess the changes in QoL in patients with Metastatic, Recurrent (M/R) HNSCC receiving MC. Materials and Methods: This was a prospective interventional hospital-based study from February 2015 to September 2018, conducted at Cancer Research Institute, Himalayan Institute of Medical Sciences, SRHU University, Dehradun, Uttarakhand, India. A total of 175 patients more than 18 years, with Eastern Cooperative Oncology Group (ECOG) performance status score <2, with M/R HNSCC, not amenable to any radical treatment, were equally distributed by lottery method in three arms, in those receiving Capecitabine (Arm A, n: 59), Celecoxib and Methotrexate (Arm B, n: 62); and placebo with best supportive care (Arm C, n: 54). In addition to demographic and baseline clinical characteristics, patients were assessed for physical examination and questioned to score their QoL by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) at presentation and followed every month for two months. Results: A total of 175 patients enrolled for the study, the mean age of study population was 56.73±6.84 years with male preponderance 77.71%. A 60% suffered from carcinoma oral cavity (n=105), followed by carcinoma oropharynx (24%) (n=42), carcinoma larynx and carcinoma hypopharynx consisted rest 16% (n=28). Altogether the QoL was quite divergent amongst the three arms. Symptom score for fatigue, dyspnoea, loss of appetite, nausea and vomiting showed rise representing worsening in Arm A and Arm C; whilst these symptoms also showed fall in symptom score in Arm B (fatigue: p-value=0.007; dyspnoea; p-value=0.042; Appetite loss: p-value=0.008 Nausea: p-value=0.02; Vomiting: p-value=0.03). There was a statistically significant improvement in overall EORTC QLQ-C30 score from baseline in the Methotrexate and Celecoxib arm (Arm B) compared with Capecitabine and with placebo. Conclusion: Metronomic Chemotherapy (MC) with Methotrexate and Celecoxib seems promising and well tolerated in patients with metastatic or advanced HNSCC as compared to Capecitabine or keeping on symptomatic treatment solely.

Download Full-text

Dynamics of quality of life of head and neck cancer patients after treatment. Clinical significance

Head and neck tumors (HNT) ◽

10.17650/2222-1468-2018-8-4-39-47 ◽

2019 ◽

Vol 8 (4) ◽

pp. 39-47

Author(s):

A. V. Karpenko ◽

R. R. Sibgatullin ◽

A. A. Boyko ◽

M. G. Kostova ◽

O. M. Nikolayeva ◽

...

Keyword(s):

Quality Of Life ◽

Head And Neck ◽

Clinical Significance ◽

Mouth Opening ◽

Emotional Function ◽

Eortc Qlq C30 ◽

Eortc Qlq ◽

Taste And Smell ◽

Sticky Saliva

The study objective is to evaluate the quality of life as one of the main parameters that determines the effectiveness of treatment of patients with head and neck squamous cell carcinoma.Materials and methods. Thirty-three stage III—IV oral cancer patients aged between 39 and 70 years were asked to fill EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30-questions) and QLQ-H&N35 (head and neck cancer-specific module) before and 12—18 months after completion of the treatment that consisted of surgery followed by radiation with or without chemotherapy. Surgery included neck dissection with removal of the primary tumor via transoral (n = 5) or combined (n = 28) approach. Reconstruction was performed by primary closure (n = 5), with pedicled (n = 8) or free (n = 20) flaps.Results. According to EORTC QLQ-C30 questionnaire only positive shifts turned out to be statistically significant: general health, emotional function, pain, insomnia and diarrhea. Site-specific EORTC QLQ-H&N35 questionnaire revealed several positive (pain in the head and neck, feeling ill, use of painkillers and weight gain) and negative (public eating, problems with taste and smell, sticky saliva and dry mouth) changes. Applying algorithms for determining clinical significance changed the number and value of several scales and domains. Changes in general health, emotional function, pain, insomnia, pain in the head and neck, taste and smell disorders, mouth opening, sticky saliva, dry mouth, painkillers and weight gain were found to have some clinical relevance. Moreover, for one of them (mouth opening) statistical significance was not reached.Conclusions. Further research of clinical significance of changes and differences in scales and domains that determine and affect quality of life are needed. They will allow to understand more fully problems that every patient with oral cavity cancer tries to cope with.

Download Full-text

Hubungan respons terapi dengan kualitas hidup penderita karsinoma nasofaring WHO tipe III setelah terapi

Oto Rhino Laryngologica Indonesiana ◽

10.32637/orli.v46i2.161 ◽

2016 ◽

Vol 46 (2) ◽

pp. 135

Author(s):

Deviana Deviana ◽

Pudji Rahaju ◽

Iriana Maharani

Keyword(s):

Quality Of Life ◽

Nasopharyngeal Carcinoma ◽

Treatment Response ◽

High Quality ◽

Cross Sectional ◽

Type Iii ◽

Eortc Qlq C30 ◽

Positive Treatment ◽

Eortc Qlq

Latar belakang: Hasil terapi penderita kanker umumnya dinilai dari angka kelangsungan hidup dan angka kontrol penyakit secara lokal/regional. Penilaian ini dilakukan oleh dokter dan tidak menunjukkan bagaimana kepuasan penderita terhadap hasil terapi. Di Indonesia, karsinoma nasofaring (KNF) menempati peringkat keempat keganasan tertinggi, dengan tipe terbanyak adalah KNF WHO tipe III. Penilaian kualitas hidup penting dilakukan karena penyakit dan terapi KNF dapat mempengaruhi beberapa fungsi penting kehidupan (makan, komunikasi, dan hubungan sosial). Belum pernah dilaporkan penelitian mengenai kualitas hidup penderita KNF setelah terapi di Indonesia. Tujuan: Mengetahui hubungan antara respons terapi dengan kualitas hidup penderita KNF WHO tipe III setelah radioterapi atau kemoradioterapi. Metode: Penelitian observasional analitik dengan pendekatan cross-sectional. Dinilai respons terapi dan kualitas hidup 8 subyek dari kelompok radioterapi, dan 8 subyek dari kelompok kemoradioterapi, dengan waktu evaluasi minimal 3 bulan setelah terapi. Penilaian respons terapi berdasarkan hasil pemeriksaan terakhir: biopsi nasofaring, foto Rontgen toraks, ultrasonografi abdomen,biopsi aspirasi jarum halus kelenjar getah bening leher (jika ada indikasi), dan foto Rontgen torakolumbal (jika ada indikasi). Penilaian kualitas hidup menggunakan kuesioner EORTC QLQ-C30 dan EORTC QLQ-H&N35. Hasil: Tidak didapati perbedaan respons terapi antara kelompok radioterapi dan kemoradioterapi. Seluruh subyek memiliki respons terapi positif (tidak didapati tumor menetap, kambuh secara lokal dan regional, dan metastasis jauh). Penderita dengan respons terapi positif memiliki kualitas hidup tinggi. Uji perbedaan kualitas hidup menunjukkan perbedaan bermakna hanya dalam hal fungsi emosi (p=0,031). Kesimpulan: Penderita KNF WHO tipe III dengan respons terapi positif memiliki kualitas hidup tinggi. Tidak didapati perbedaan respons terapi antara kelompok radioterapi dengan kemoradioterapi. Penderita yang mendapatkan kemoradioterapi memiliki kualitas hidup lebih tinggi dalam hal fungsi emosi.Kata kunci: Karsinoma nasofaring, radioterapi, kemoradioterapi, respons terapi, kualitas hidupABSTRACT Introduction: The endpoint of medical care for cancer patients usually focused on the survival rate and locoregional control rate. These endpoints were assessed by doctor and not the patient’s satisfaction rate to treatment outcome. In Indonesia, nasopharyngeal carcinoma (NPC) is the fourth most common cancer, especially NPC type III WHO. Assessment of quality of life is important because both the disease and the therapy of NPC could affect several important functions in life (eating, communication, and social relationships). There was no study reported about quality of life of NPC patients after therapy in Indonesia. Purpose: To assess the relationship between treatment response and quality of life of NPC WHO type III patients after radiotherapy or chemoradiotherapy. Method: Analytic observational study with cross-sectional design assessed treatment response and quality of life in 8 subjects of radiotherapy group and 8 subjects of chemoradiotherapy group with minimal evaluation time 3 months after therapy. Treatment response was assessed by the latest examination result of nasopharyngeal biopsy, thorax plain photo, abdomen ultrasonography, fine needle aspiration biopsy of neck mass (if indicated), and thoracolumbal plain photo (if indicated). Quality of life was assessed by EORTC QLQ-C30 and EORTC QLQ-H&N35 questionnaire. Result: There was no treatment response difference between radiotherapy and chemoradiotherapy group. All subjects had positive treatment response (no cancer remained, no locoregional recurrence, and no distant metastasis). Subjects with positive treatment response had high quality of life. Statistical analysis on the quality of life only showed a marked difference in emotional function (p=0.031). Conclusion: NPC WHO type III patients with positive treatment response had high quality of life. There was no treatment response difference between radiotherapy and chemoradiotherapy subjects. Patients treated with chemoradiotherapy had a better quality of life in emotional function.Keywords: Nasopharyngeal carcinoma, radiotherapy, chemoradiotherapy, treatment response, quality of life

Download Full-text